Probiotic Strains Enhancing Intestinal Barrier via TLR2 Signaling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents fail to effectively target and enhance the intestinal tight junction barrier, which is a pathogenic factor in inflammatory conditions such as inflammatory bowel disease and extends to conditions like alcoholic liver disease, with mechanisms poorly understood and no available drugs targeting this barrier.
Innovation Solution
The use of specific probiotic bacterial strains like Lactobacillus acidophilus (ATCC 4356) and Bifidobacterium bifidum (ATCC 35914) that interact with the TLR2 receptor complex, activating signal transduction pathways to increase occludin expression and enhance intestinal tight junction barrier function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapeutic agents are used, then treatment of inflammatory conditions is provided, but they fail to effectively target and enhance the intestinal tight junction barrier
Solution Approach 1:
The patent uses probiotic bacteria (Lactobacillus acidophilus and Bifidobacterium bifidum) as intermediary agents that naturally interact with the intestinal tight junction barrier. These probiotics express TLR2 agonists that mediate the enhancement of tight junction function, providing a biological intermediary mechanism that current synthetic therapeutic agents cannot achieve.
2Reliability
If probiotic strains are used to enhance tight junction barrier, then intestinal permeability decreases, but the mechanism was previously poorly understood
Solution Approach 1:
The patent establishes a feedback mechanism where probiotic bacteria express TLR2 agonists that activate signaling pathways (MyD88-dependent) leading to increased occludin expression. This creates a measurable feedback loop: probiotic administration → TLR2 activation → occludin upregulation → enhanced tight junction function → decreased intestinal permeability, which was previously unknown.
3Reliability
If probiotic bacterial species expressing TLR2 agonist are administered, then intestinal epithelial barrier function is enhanced, but this requires specific probiotic strains with particular characteristics
Solution Approach 1:
The patent applies local quality by specifying particular probiotic strains (Lactobacillus acidophilus ATCC 4356 and Bifidobacterium bifidum ATCC 35914) that possess the unique property of expressing TLR2 agonists. Not all probiotic strains have this capability, so the invention identifies and utilizes strains with this specific local quality to achieve the desired therapeutic effect.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These probiotic strains significantly increase transepithelial electrical resistance and decrease intestinal permeability, providing therapeutic efficacy in animal models of IBD and liver disease, with synergistic effects when used in combination.
Implementation Method 1
interact with the TLR2 receptor complex, activating signal transduction pathways to increase occludin expression
Implementation Method 2
significantly increase transepithelial electrical resistance and decrease intestinal permeability
Data Source
AI summary
This disclosure describes compositions and methods involving amounts of probiotic bacteria effective to decrease intestinal permeability or intestinal epithelial tight junction permeability in a subject having or at risk of having defective intestinal barrier, increased intestinal permeability and/or intestinal epithelial tight junction permeability compared to a normal subject. The probiotic bacteria can include a Lactobacillus spp. and/or a Bifidobacterium spp.